Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%
After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG)
After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG)
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion
Disc Medicine (IRON) Down on Mixed Results From AURORA Study
Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
Moderna (MRNA) Posts Pipeline Progress, Secures Blackstone Funding
Praxis (PRAX) Surges on Positive Epilepsy Study Results
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA
Novo Nordisk (NVO) Gets Positive CHMP Opinion for Insulin Icodec
Lifecore (LFCR) Down 30% on Ending Strategic Review With No Deal
Bayer's (BAYRY) Elinzanetant Meets Goals in Third Phase III Study
Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.